ClinicalTrials.gov
ClinicalTrials.gov Menu

Exercise, Prostate Cancer and Circulating Tumour Cells (ExPeCT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02453139
Recruitment Status : Completed
First Posted : May 25, 2015
Last Update Posted : May 2, 2018
Sponsor:
Information provided by (Responsible Party):
Prof Stephen Finn, University of Dublin, Trinity College

Brief Summary:
Obesity, known to be associated with a pro-inflammatory, pro-thrombotic humoral milieu, confers a worse prognosis in prostate cancer (PrCa). Circulating tumour cells (CTCs) are identified in the blood in advanced cancer. Their quantitation provides prognostic information. "Cloaking" of CTCs by adherent platelets impedes natural killer (NK)-cell clearance of CTCs from the circulation, enhancing metastatic spread. NK-cell function in blood and in solid organs is quantitatively and qualitatively reduced in obesity. Platelet cloaking may be enhanced in obesity due to the pro-inflammatory, pro-thrombotic state, and may be a mechanism for worse cancer-specific outcomes in this group. Obesity and its biochemical effects may be influenced by lifestyle changes such as exercise. Physical activity reduces levels of systemic inflammatory mediators and so an aerobic exercise intervention may represent an accessible and cost-effective means of ameliorating the pro-inflammatory effects of obesity. The ExPeCT trial will determine if a prescribed exercise intervention can ameliorate the degree of platelet cloaking in obese and non-obese men with advanced prostate cancer.

Condition or disease Intervention/treatment Phase
Prostate Cancer Obesity Behavioral: Exercise Not Applicable

Detailed Description:

The overarching hypothesis is that enhanced platelet cloaking of circulating tumour cells in obese men with prostate cancer, due to increased systemic inflammation, is a mechanism underlying worse prognosis of cancer in these patients.

The investigators aim to test the following four hypotheses, dividing the experimental and analytical work into four separate projects.

  1. Platelet cloaking of circulating PrCa tumour cells is more prominent in men with obesity than without
  2. Regular exercise can ameliorate platelet cloaking
  3. The degree of platelet cloaking varies with levels of systemic and primary tumour inflammation and coagulability
  4. Expression of an obesity-associated lethality gene signature leads to variation in platelet cloaking

For the first hypothesis, 200 men with metastatic PrCa will be recruited, and divided into exposed and non-exposed groups based on body mass index (BMI >25). The objective will be to enumerate CTCs and quantify the degree of platelet cloaking in exposed and non-exposed groups, and to draw meaningful comparisons between the two.

For the second hypothesis, the objective will be to determine to what extent the number of CTCs and the degree of platelet cloaking varies in exposed and non-exposed groups following a supervised exercise intervention, and to compare this with a non-exercised comparison group. The exercise intervention will prescribe moderate intensity aerobic exercise that will be supervised once per week for 3 months and completed independently at home for a further 3 months. Patients will wear Polar heart rate monitors to monitor exercise prescription and progression. Assessments including blood sampling and quality of life questionnaires will be completed at baseline, 3 months and 6 months.

For the third hypothesis, the objective will be to build a serological, haematological and immunological picture of the state of systemic inflammation and coagulability, and the degree of inflammation within the prostate gland. Furthermore, the investigators intend to correlate and compare these variables with the results of the first and second objectives, in order to determine whether the number of CTCs and the degree of platelet cloaking varies with changes in the inflammatory / coagulatory milieu.

For the fourth hypothesis, the objective will be to determine whether the expression profile of a number of lethality-associated genes, known to be associated with PrCa progression, coagulation and stem-cell like phenotype, correlates with the number of CTCs and the degree of their cloaking by platelets.

CTC numbers and the degree of platelet cloaking will be common denominators which anchor these four objectives together and enable comparison between them.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 67 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Evasion of Immune Editing by Circulating Tumour Cells in an Exercise Modifiable Mechanism Underlying Aggressive Behaviour in Obese Men With Prostate Cancer
Study Start Date : October 2014
Actual Primary Completion Date : June 2017
Actual Study Completion Date : June 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Exercise group
6 month supervised and home based moderate intensity aerobic exercise programme
Behavioral: Exercise
6 month supervised and home based aerobic exercise intervention

No Intervention: Control
Non-exercising control group receiving usual care



Primary Outcome Measures :
  1. Change in Platelet cloaking of Circulating Tumour Cells [ Time Frame: Change from baseline in platelet cloaking of circulating tumours cells at 3 months and 6 months ]
    Enumeration of circulating tumour cells and degree of platelet cloaking of CTCs


Secondary Outcome Measures :
  1. Change in systemic inflammation [ Time Frame: Change in cytokines from baseline in inflammation at 3 months and 6 months ]
    Blood samples will be taken from participants at each assessment and analysed by multi-plex assays for levels of cytokines (TNF-alpha and interleukin (IL)-6

  2. Change in Quality of Life Questionnaire [ Time Frame: Change from baseline in quality of life at 3 months and 6 months ]
    Participants will complete quality of life questionnaires assessing a range of issues including sleep, diet quality and physical activity at each assessment



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Written informed consent obtained before any study-related procedures
  2. Age ≥ 18 years and male
  3. Histologically confirmed diagnosis of prostate adenocarcinoma
  4. Metastatic disease as confirmed by CT/MRI or by bone scan
  5. Stable medical condition, including the absence of acute exacerbations of chronic illnesses, serious infections, or major surgery within 28 days prior to randomisation
  6. Capable of participating safely in the proposed exercise intervention as assessed and signed off by a treating physician involved in ExPeCT recruitment.

Exclusion Criteria:

  1. No history of radical prostatectomy
  2. No previous diagnosis of any other malignant tumour (patients with non-melanoma skin cancer or carcinoma in situ of any type are not excluded provided they have undergone complete resection)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02453139


Locations
Ireland
Adelaide and Meath Incorporating the National Children's Hospital
Tallaght, Dublin, Ireland, 24
St James's Hospital
Dublin, Ireland, 8
Beaumont Hospital
Dublin, Ireland
Mater Misericordiae University Hospital
Dublin, Ireland
St Luke's Hospital
Dublin, Ireland
United Kingdom
Guy's St Thomas
London, United Kingdom
Sponsors and Collaborators
University of Dublin, Trinity College
Investigators
Principal Investigator: Stephen Finn Trinity College Dublin

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Prof Stephen Finn, Professor, University of Dublin, Trinity College
ClinicalTrials.gov Identifier: NCT02453139     History of Changes
Other Study ID Numbers: 202370
First Posted: May 25, 2015    Key Record Dates
Last Update Posted: May 2, 2018
Last Verified: May 2018

Additional relevant MeSH terms:
Prostatic Neoplasms
Neoplastic Cells, Circulating
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases
Neoplasm Metastasis
Neoplastic Processes
Pathologic Processes